← Back to headlines
Precigen, Cytosorbents Project Cash Flow Breakeven by 2026
Biotech companies Precigen and Cytosorbents have both projected reaching operating cash flow breakeven by late 2026 or early 2027. These targets are linked to the scaling of product launches and planned regulatory submissions.
14 May, 02:41 — 14 May, 02:41
Sources
Showing 1 of 1 sources
